Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product

STAMFORD, CT--(BUSINESS WIRE)--Experts from Philip Morris International Inc. (NYSE: PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP). The full-day meeting on October 7 was part of the FDA's customary review of PMI's request to continue marketing versions of its IQOS heated tobac. ...